hoxa9 and its role in acute myeloid leukemia

9
HOXA9 and its Role in Acute Myeloid Leukemia Brent Hoffman

Upload: bin

Post on 24-Feb-2016

30 views

Category:

Documents


0 download

DESCRIPTION

HOXA9 and its Role in Acute Myeloid Leukemia. Brent Hoffman. HOXA9 is one of the HOX transcription factors regulating Anterior to Posterior patterning in early development. HOXA9 regulates bone marrow stem cell proliferation and cells differentiate as HOXA9 expression decreases. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: HOXA9 and its Role in Acute Myeloid Leukemia

HOXA9 and its Role in Acute Myeloid

LeukemiaBrent Hoffman

Page 2: HOXA9 and its Role in Acute Myeloid Leukemia

HOXA9 is one of the HOX transcription factors regulating Anterior to Posterior patterning in early development

Page 3: HOXA9 and its Role in Acute Myeloid Leukemia

HOXA9 regulates bone marrow stem cell proliferation and cells differentiate as

HOXA9 expression decreases

Page 4: HOXA9 and its Role in Acute Myeloid Leukemia

HOXA9 -/- bone marrow cells showed inhibited ability to repopulate in vitro after

hematopoietic stress

Page 5: HOXA9 and its Role in Acute Myeloid Leukemia

Acute Myeloid Leukemia is a cancer of the bone marrow affecting white blood cell proliferation and differentiation

Page 6: HOXA9 and its Role in Acute Myeloid Leukemia

In AML, a translocation joinsHOXA9 to NUP98

Page 7: HOXA9 and its Role in Acute Myeloid Leukemia

Fusion of the NUP98 gene to HOXA9 induces AML in mice cells

Page 8: HOXA9 and its Role in Acute Myeloid Leukemia

Current treatment for AML is divided into two phases: remission induction and post-remission therapy

Page 9: HOXA9 and its Role in Acute Myeloid Leukemia

References• “Acute Myelogenous Leukemia (AML).” Mayoclinic. Mayo Clinic Staff, 5 Sept. 2012. Web. 4-4/13.

<http://www.mayoclinic.com/health/acute-myelogenous-leukemia/DS00548/DSECTION=treatments-and-drugs>.• “Acute Myelogenous Leukemia.” Cleveland Clinic. Web. 4–11 2013.

<http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/acute-myelogenous-leukemia/>.

• “Adult Acute Myeloid Leukemia Treatment (PDQ®).” National Cancer Institute . Web. 11–4 2012. <http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/Patient/page3>.

• “Algorithmic and Topological Body Plans.” Web. 11–4 2012. <http://www.19thpsalm.org/Ch09/Algorithm-Topology.html>.• Gough, S. M., Slape, C. L., & Aplan, P. D. (2011). NUP98 gene fusions and hematopoietic and new biologic insights

malignancies: common themes . Blood, 118(24), 6247–6257. Retrieved from http://bloodjournal.hematologylibrary.org/content/118/24/6247.full.pdf+html

• Hematopoeisis from Multipotent Stem Cells. (2012). Retrieved from http://www.ebioscience.com/resources/pathways/hematopoiesis-from-multipotent-stem-cells.htm

• “Hematopoietic Stem Cell Transplantation (HSCT) and Cerebral ALD.” Web. 4–11 2013. <http://www.x-ald.nl/treatment-options/hsct/>.

• Kroon, Evert et al. “NUP98–HOXA9 Expression in Hemopoietic Stem Cells Induces Chronic and Acute Myeloid Leukemias in Mice.” The EMBO Journal 20.3 (2001): 350–361. NCBI. Web. 4–11 2013. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC133485/>.

• Lawrence, Jeffrey H et al. “Loss of Expression of the Hoxa-9 Homeobox Gene Impairs the Proliferation and Repopulating Ability of Hematopoietic Stem Cells.” Blood 106.12 (2005): 3988–3994. Print.

• “Typical Treatment of Acute Myeloid Leukemia (except Promyelocytic M3).” American Cancer Society. Web. 11-4/13. <http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-treating-typical-treatment-of-aml>.